Porvasnik et al. reported that CTCE-9908 treatment reduced tumor angiogenesis by down regulating VEGF production and myeloid derived suppressor cell (CD11b positive) recruitment into tumor tissues [22]. The gene discussed is VEGFA; the disease is neoplasm.